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Abstract
Background: It is believed increasingly that patients with severe Crohn’s disease are best treated early with biological
therapy, which may ameliorate subsequent disease course and diminish long-term complications. However, we cannot
predict currently which new presentations of Crohn’s disease are destined to develop severe disease so treatment
cannot be targeted to the most appropriate patients. Accordingly, via systematic review and meta-analysis we aim to
identify if biomarkers of disease activity are able to predict development of severe disease.
Methods/design: We will search the primary literature and conference proceedings for studies of biomarkers of all
types including clinical, endoscopic, radiological, faecal, urinary, serological, genetic, and histological. Precise definition
of “severe” disease is elusive so we will include sensitivity analysis to account for different definitions. We will use the
CHARMS checklist to frame our question and to extract data. We will extract the study design, setting, participant
characteristics, biomarker(s) investigated, and study outcomes. Bias will be assessed via the PROBAST tool. We will
present the results using narrative and graphical methods. We will present the summary by meta-analysis where there
are sufficient studies with reasonable homogeneity, using methods appropriate to the type of data extracted.
Heterogeneity will be presented via Forest and ROC plots.
Discussion: If this systematic review and meta-analysis identifies biomarkers that appear sufficiently predictive for
subsequent severe disease course, we aim to combine them in a predictive model, followed by external validation
using individual patient data. A predictive model able to identify new presentations of Crohn’s disease destined to
develop severe disease subsequently would have considerable clinical utility for patient management.
Systematic review registration: PROSPERO CRD42016029363.
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Background
Crohn’s disease and modern treatment strategy
Crohn’s disease is an inflammatory ulcerative enterop-
athy that tends to affect young adults and can be
extremely debilitating. There is no cure, and treatment
is traditionally applied in a “bottom-up” fashion, directed
at symptoms when they arise and escalated when symp-
toms worsen. However, newer biological therapies
appear to ameliorate ultimate disease trajectory, raising
the possibility that early “top-down” treatment with
these agents could “stop the disease in its tracks”. The
first disease-modifying biological agent was infliximab, a
monoclonal antibody against the cytokine TNF-α, bind-
ing with it and preventing receptor binding. A rando-
mised trial of infliximab versus placebo found that of
patients responding to an initial dose, half achieved
complete mucosal healing after 1 year, stayed in remis-
sion longer, and discontinued steroids earlier than con-
trols [1]. Biologicals also appear incrementally more
effective when used in combination with other immuno-
modulators such as azathioprine [2], especially when
administered in a “top-down” fashion [3, 4]. Newer
agents such as adalimumab are also effective [5].
The REACT study randomised patients to conven-
tional “bottom-up” therapy or “early combined immuno-
suppression”, finding major complications, hospitalisation
and surgery reduced significantly at 24 months for inter-
vention clusters [6]. Accordingly, current thinking is that
early aggressive biological treatment combined with
immunomodulation will prevent future disease and is
preferable than merely responding to symptoms. However,
administering biologicals early to all patients is unwise
because these agents may precipitate serious infection, are
hepatotoxic, and can cause demyelination, lupus syn-
drome and even lymphoma [7]. Biologicals are also very
expensive. A strategy that could identify new diagnoses of
Crohn’s disease destined to develop severe disease in the
future would have considerable clinical utility by directing
these patients to early biological treatment while avoiding
this in others.
Biomarkers of disease activity
Optimal therapeutic response can be defined by “deep
remission”, a term that describes complete mucosal heal-
ing combined with Crohn’s disease activity index
(CDAI) < 150, and which identifies patients who are
responding to biological therapy where administered
(although deep remission is not necessarily associated
with severe disease in and of itself ). Confident diagnosis
of deep remission currently requires direct visualisation
of the endoluminal bowel via endoscopy but the small
bowel is most affected by Crohn’s disease (circa 75% of
patients), while being relatively inaccessible to endos-
copy; push enteroscopy is technically difficult and
invasive, and capsule endoscopy is contraindicated in
patients with bowel strictures, which are common in
Crohn’s disease. A more acceptable “biomarker” acting
as an effective surrogate for deep remission (and thus
disease activity/response to therapy) would have great
clinical utility.
According to the USA National Institute of Health, a
biomarker is, “a characteristic that is objectively mea-
sured and evaluated as an indicator of normal biologic
processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention.” Biomarkers in
Crohn’s disease may be able to indicate the presence or
absence of disease and its severity. We do not wish to be
too restrictive when labeling an intervention or charac-
teristic as a “biomarker”. While the term is associated
with novel diagnostic technologies, simple and effective
biomarkers have been used for decades. For example,
stool frequency reflects colonic inflammation directly
and should not be excluded from systematic review
because it is not “novel”. Smoking has a profound effect
on disease outcome and should be included although
smoking, in and of itself, is not a marker of disease activ-
ity. Several studies have investigated simple clinical factors
predictive of an “aggressive” disease course and the
Markov modelling of these has shown that disease activity
over the year following diagnosis is predictive of clinical
course over the following decade [8].
We therefore wish to identify the whole range of
potential biomarkers used in Crohn’s disease, including
clinical (both clinician and self-reported outcomes),
endoscopic, radiological, faecal, urinary, serological
(including the range from basic tests to antibodies), gen-
etic, and histological. For example, C-reactive protein
(CRP) is an acute-phase protein expressed by the liver
that is used widely in clinical practice. Calprotectin, a
protein released in an inflamed gut epithelium, is a more
recent biomarker that has also reached daily practice.
Calprotectin levels change with treatment. Lactoferrin is
a similar protein biomarker. We anticipate that the diag-
nostic accuracy of such biomarkers may already have
been subject to systematic review and meta-analysis. For
example, one such review aimed to determine if calprotectin
levels could differentiate between inflammatory and irritable
bowel disease in children [9].
Because we anticipate that there will be many potential
biomarkers, we will set quality/quantity thresholds for
review inclusion that prevent us from extracting data for
biomarkers that have been studied in insufficient num-
bers and/or with weak methodology (see the inclusion
criteria below). For example, at the time of writing, more
than 70 separate genes have been implicated in Crohn’s
disease [10]. While genetic sequencing is presently very
expensive and many individual genes have been studied
in little depth, sequencing will become more cost-effective
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in the near future. Our systematic review must therefore
consider those genes where sufficient primary studies
exist. Genetic makeup is also linked to response to
biological therapy. Since genetic makeup is fixed, these
factors need only be measured once, as opposed to other
biomarkers that fluctuate with disease activity. There are
also multiple antibody candidates and prognostic strat-
egies that have focused on both the titres of individual
antibodies and the number of different antibodies. For
example, patients with three or more positive antibodies
are eight times more likely to need surgery than negative
patients [11].
The need for a systematic review
The United Kingdom National Institute for Health
Research (NIHR) Health Technology Assessment (HTA)
Programme has funded a systematic review and meta-
analysis of the indexed medical literature to identify bio-
markers that may be able to identify patients with
Crohn’s disease who are destined to develop severe dis-
ease and who may therefore benefit from early biological
therapy (see Acknowledgements). It is hoped that early
identification of such patients will ameliorate the course
of their future disease while avoiding overtreatment
in others who do not need it or who will not
respond. Achieving this necessitates the development
of a prognostic model fed by data identified from
systematic review.
Results from a scoping review
We performed an initial “scoping review” in order to as-
sess data likely available, both in terms of the individual
biomarkers and the volume of studies associated with
each. The scoping review was performed by a clinical
researcher with content expertise in Crohn’s disease
(GB), supervised by a senior member of the research
team (SH) and was confined to 2013. Search terms and
results are presented in Table 1. We focused our atten-
tion on the 35 clinical trials identified, and 13 appeared
potentially eligible for a systematic review. We then
investigated the following questions: Was it possible to
extract data for Crohn’s disease severity (i.e. severe vs.
non-severe); were new presentations reported, and could
they be extracted separately; could a 2 × 2 results table
be extracted for the biomarker(s) in question; was prog-
nostic information provided?
As anticipated, there was little overlap in biomarkers
investigated by individual studies. A wide range was
studied that included vitamin D, granulocyte macro-
phage colony-stimulating factor (GM-CSF), DCE/DWI
MRI, CDAI and CRP, serum calprotectin, faecal
S100A12, nitric oxide, serum serotonin, NOD2insC, oxida-
tive stress markers, thiopurine metabolites, anti-neutrophil
cytoplasmic antibodies, and anti-saccharomyces cerevisiae
mannan antibodies. Based on the scoping data, we antici-
pate that the number of potential biomarkers potentially
available is large but proportionally few will be reported in
detail sufficient for meaningful meta-analysis, that most
studies will describe patients who relapse rather than new
presentations, that specific identification of patients with
severe disease will be difficult, that extracting 2 × 2 tables
will only be possible from a minority of papers without
contacting the authors and that existing models will be
encountered rarely.
Objectives
Our primary objective is as follows:
1. To perform four systematic reviews of the literature
that cover separate biomarker areas, to assess
biomarker-predictive ability for severe Crohn’s
disease. Four reviews are necessary because we
anticipate a wide range of biomarkers. The biomarker
areas will be as follows: (1) serological and urinary, (2)
clinical, imaging and endoscopic (including patient
characteristics and symptoms), (3) genetic and (4)
combinations of tests/biomarkers. Ultimately, we will
summarise evidence across all four reviews thereby
producing an overall synopsis (the protocol presented
here is “generic”, intended to cover the four reviews
and overview).
Our secondary objectives are as follows:
1. To compare predictors using direct and indirect
comparison of study results. Direct comparisons
between predictors from the same study constitute
stronger evidence and will be preferred over indirect
comparisons across different studies.
2. To explore heterogeneity among studies by analysing
subgroups classified as specified in Additional file 1.
3. To conduct sensitivity analyses to examine our main
assumptions and definitions as specified in
Additional file 1. In addition, we will conduct
Table 1 Results of scoping review to identify studies of biomarkers
in Crohn’s disease, performed in March 2015
Search term Number of
articles
identified
Number of
clinical trials
identified
Crohn’s disease 41,158 1962
Crohn’s 41,322 1867
All MeSH terms for Crohn’s disease 42,373 1992
All MeSH terms for biological markers 848,207 45,368
Crohn’s disease all MeSH terms and
biological markers all MeSH terms
3308 225
Limit to 2013 338 35
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sensitivity analysis based on studies with low or unclear
risk of bias, i.e. excluding studies at a high risk of bias.
4. To develop and validate a prognostic model to
identify patients destined to develop severe Crohn’s
disease and who may therefore respond to early
biological therapy. We will develop our own model
using predefined predictor combinations identified
via the prior systematic review. We will externally
validate our model via individual patient data (IPD).
We will also examine and validate any existing
models identified via systematic review.
The ability to examine primary and secondary objec-
tives will be highly dependent on the availability and
quality of data from published studies.
Methods/design
Ethical approvals
Ethical permission is not required by our institution for
systematic reviews of available medical literature.
However, the validation phases of the proposed research
will require IPD. In the first instance, we anticipate IPD
being drawn from the METRIC [12] and PANTS trials
(http://public.ukcrn.org.uk/search/StudyDetail.aspx?Study
ID=14175), to which we have IPD access. The ethical
permissions necessary to access and use these data for the
purpose of developing and validating a prognostic model
will be sought. Should we fail to achieve the ethical
approval, then this aspect of the study will not proceed.
This protocol has been drafted in line with the
PRISMA-P checklist (Additional file 2).
Eligibility criteria for inclusion in the review
 Primary studies will report patients with a proven
diagnosis of Crohn’s disease in whom a biomarker(s)
is used to predict the development of a severe
disease (or vice versa).
 We will apply no age restriction but will extract
paediatric subsets where these are reported (defined
as age less than 16 years).
 Both new and established diagnoses of Crohn’s
disease will be eligible because, while our focus is
prediction of patients destined to develop severe
disease (which implies that primary studies include
patients with a new diagnosis), we anticipate that
the large majority of studies will investigate patients
with an established disease since these are far more
numerous and accessible to researchers. Where
possible, we will extract information relating to new
and established subsets separately.
 Studies reporting all severities of Crohn’s disease will
be eligible. Where available, we will extract
information relating separately to subsets of patients
with “severe” and “non-severe” disease (see explanatory
paragraph below).
 Individual biomarkers will be reported in at least five
individual primary studies.
 Not more than five individual biomarkers identified
as “promising” by an expert panel but reported in
less than five individual primary studies will be
included in each of the four systematic reviews that
we intend to conduct.
 Any univariable or multivariable models identified
that report predictors of severe disease for patients
with proven Crohn’s disease. In the case of models,
we will extract data irrespective of the number of
models that report an individual predictor or
combination of predictors.
 We will apply no language restriction (we will
arrange for translation for potentially important
non-English research although we anticipate this will
be a small proportion).
A precise definition of “severe” disease is elusive. The
Montreal classification (a modification of the Vienna
classification) is a phenotypic classification based on age
at diagnosis, disease location, and disease behavior; stric-
turing (B2) and penetrating (B3) disease (together, 20%
of patients) comprise those with severe disease [13]. The
term “disabling Crohn’s disease” was introduced in 2006
[14] and includes patients presenting under 40 years of
age, steroid dependency, hospitalisation, persistent
symptoms for more than 1 year in a five-year period,
extra-intestinal complications (notably perianal disease),
a need for surgery, and a need for immunosuppression.
The UK National Institute for Healthcare and Clinical
Excellence technology appraisal guidance 187 of May
2010 titled “Infliximab (review) and adalimumab for the
treatment of Crohn’s disease”, defined severe disease as
“very poor general health and one or more symptoms
from weight loss, fever, severe abdominal pain and usu-
ally frequent (3–4 or more) diarrhoeal stools daily[15].
People with severe active Crohn’s disease may or may
not develop new fistulae or have extra-intestinal mani-
festations of the disease”. The NICE guidance goes on to
state that “This clinical definition normally, but not
exclusively, corresponds to a Crohn’s disease activity
index (CDAI) score of 300 or more, or a Harvey-Bradshaw
score of 8 to 9 or above.”
We will therefore not stipulate a single definition of
“severe” disease for primary studies since we believe
this would result in excessive discarded data, but will
include sensitivity analysis for the different definitions
of severe disease encountered. We will also consult
our investigator group and collaborators so as to
arrive at a robust and generally accepted definition of
“severe” for the purposes of this review once we are
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aware of the range of definitions presented in the
extracted data.
It should also be noted that our remit is to distinguish
patients with Crohn’s whose disease is destined to be-
come severe from those whose disease is not destined to
become severe. Studies that employ controls that do not
have Crohn’s disease (e.g. normal volunteers) may iden-
tify factors that are significantly associated with Crohn’s
disease, but it is important to appreciate that such
factors may not be associated with “severe” disease. Such
studies will be included in the review and data relating
to disease onset, severity and biomarker(s) extracted as
described elsewhere. It is also possible that there will be
biomarkers that identify non-severe disease, the absence
of which could identify patients with severe disease.
In advance of the study identification and extraction,
we will convene our investigator group to discuss a
priori criteria that define whether an individual bio-
marker has been researched in enough depth to present
a reasonable chance that primary studies will be suffi-
cient to permit an accurate reflection of diagnostic
accuracy via meta-analysis. A simple metric will be
required, likely related to the individual number of pri-
mary studies identified for a specific biomarker in com-
bination with a minimum number of patients studied by
each. Our group will also define the date range over
which primary studies will be identified; at the time of
writing, we anticipate this will be from 1980 to the
present day.
Search strategy
We will use resources that enable us to search multiple
databases simultaneously, from 1980 until the present
day: the biomedicine subset of UCL MetaLib searches
AHMED, BioMed Central, CINAHL plus, Cochrane,
EMBASE, OVID, Pubmed and SCOPUS. We will report
our search string as an Appendix to published studies.
We will handsearch conference proceedings (European
Crohn’s and Colitis Organisation, United European
Gastroenterology Week, Digestive Disease Week) from
2012 to date inclusive in order to identify grey litera-
ture. A draft for the search strategy to be used for
the PUBMED online database is reproduced in
Additional file 3.
We will identify predictors recommended or men-
tioned in clinical guidelines or recommendations from
established clinical associations (e.g. European Crohn’s
and Colitis Organisation, ECCO; European Society of
Gastrointestinal and Abdominal Radiology, ESGAR). Via
our expert panel, we will identify prespecified predictors
that are already in widespread clinical use. So as to not
miss new predictors, our expert panel will also identify
recent “promising” markers from abstracted data pre-
sented at relevant subspecialty meetings during the
2 years prior to the review, which have not yet appeared
in sufficient indexed articles to meet our inclusion cri-
teria. In order to avoid being swamped by large numbers
of abstracted biomarkers studied in insufficient depth,
we will limit the number selected to no more than five
“promising” predictors for each individual review.
Data collection
We will follow the CHARMS checklist for framing our
systematic review question and to extract data [16]. To
reduce costs, a single clinical researcher (DB) with con-
tent expertise in Crohn’s disease will perform the bulk of
the extraction. In order to ensure that extraction pro-
ceeds correctly and in an unbiased fashion, we will pilot
data extraction on a subset of 20 papers extracted by
both the researcher and the senior members of the team
(SH, SM). This procedure will assess both adequacy of
the extraction sheet to capture the data necessary and
also provide an opportunity to assess an inter-observer
agreement. If disagreement is <5% (which we anticipate
for these type of data following the scoping review de-
scribed above) we will proceed with a single researcher.
If we identify a particular item as problematic, a second
researcher will also review this item. From our prior
experience, we anticipate any difficulties will most likely
relate to extraction of 2 × 2 tables and other numerical
results, and so the second researcher will likely be a stat-
istician. The researcher(s) performing the extraction will
have easy access to senior members of the research team
when questions arise regarding primary study suitability
both for inclusion and/or the precise nature of the data
extracted (methodology experts SM, SH and disease
experts TA, SB).
Following piloting, DB will screen the titles and
abstracts of all primary studies identified by the search
string and determine whether these meet the inclusion
criteria. Data will be extracted into the study extraction
sheet developed specifically for the review; development
will occur at a series of face-to-face meetings of the core
research team. Where necessary, the statistician will help
with the extraction of data for meta-analysis. Additional
data will be sought from authors of primary studies
where appropriate.
Data items to be extracted
The extraction sheet will include the following items as
a minimum:
 Details of study design (e.g. cohort, randomised
controlled trial, retrospective database, routinely
collected data) and study methods.
 Setting/context (organisation/service type, country).
 Participants, including age and range, gender,
whether the diagnosis is new or established
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(symptom duration and/or time since diagnosis for
established disease), symptom severity (and how this
is defined), disease location and burden, disease
complications, HBI, CDAI etc. (where these are not
the primary biomarker under investigation), details
of any surgery, anal disease and continence
outcomes. As noted previously, we expect the exact
definitions of severe disease and disease remission to
vary between studies so we will note specific
definitions and include sensitivity analyses for
definitions of outcomes.
 Biomarker(s) used/investigated (including pre-analytical
methods and analytic measurement methods, frequency
of measurement), adverse events related to biomarker
administration, reliability and reproducibility of
biomarker measurements.Where available, we will
collect information on unit costs of biomarkers.
 Where biomarker measurement could result in
adverse effects, we will collect relevant information
to summarise these data. We will highlight issues
and information where available on the reliability
and reproducibility of biomarker measurements,
including how this may affect reliability of predictions
using these biomarkers.
 Study interventions and outcomes (including
definitions, thresholds for severity/remission and
whether prespecified), median follow-up time with
interquartile range and range (we will conduct
sensitivity analyses for different time intervals).
 We will consult both our patient and public
involvement (PPI) representative and METRIC/
PANTS expert panels to identify other important
outcomes.
Where models are encountered, we will extract the
type of model study (development, internal validation or
external validation), included predictors (including
methods of measurement, categorisation of continuous
outcomes, blinding to outcome assessment and pre-
dictor variables), sample size (number of participants
with events and included in modelling), statistical mod-
elling methods where present (including model fitting,
treatment of missing data, methods used to adjust for
overfitting), model performance (discrimination, calibra-
tion, sensitivity, specificity, net benefit, reclassification),
model estimates and 95% confidence intervals (e.g.
unvariable unadjusted or adjusted estimates for predic-
tors, adjusted coefficients for predictors in multivariable
models). We anticipate that data may include estimates
with 95% CI including odds ratios (OR), risk ratios (RR),
hazard ratios (HR), survival curves and log rank esti-
mates for time-to-event models, sensitivity, specificity,
positive predictive value, and negative predictive value.
Where possible we will extract 2 × 2 tables underlying
the data using excel conversion spreadsheets: For data
expressed using sensitivity/specificity/NPV/PPV, we will
use methods developed by Deeks and Snell (Deeks and
Snell, personal communication), and for data expressed
as hazard ratios or survival curves we will use methods
based on Tierney [17] and Parmar [18]. Unadjusted esti-
mates will be preferred, with adjusted estimates only
where unadjusted are unavailable.
Assessment of risk of bias in individual studies
We will use the PROBAST (Prediction study Risk Of
Bias ASsessment Tool) to assess the risk of bias in pre-
diction modelling studies using a prepublication version
with permission of the PROBAST Steering group [19].
The tool has five broad domains: patient selection, index
test, reference test, flow and timing and analysis. At the
present stage, we intend to omit the fifth domain for as-
sessment of single predictors from univariable analyses.
Summary measures and results synthesis
We will present results using narrative and graphical
methods, where study results are obviously heteroge-
neous by visual inspection, or where results from differ-
ent studies are presented using statistical measures that
we cannot combine, or for multivariable prediction
models with few studies (where we will extract data even
if there are fewer than five studies).
We will use the following methods where there are
sufficient studies allowing extraction of results in the
same format with reasonable homogeneity to allow sum-
mary by meta-analysis:
 For time-to-event data, we will use random effects
inverse variance meta-analysis methods (DerSimonian
and Laird) where hazard ratios and standard errors
can be extracted [20].
 For odds ratios extracted as 2 × 2 tables, we will use
stratified one-stage random effects models, ensuring
correct clustering of patients within studies by using
separate intercepts for each study [21, 22]. The binary
one-step approach using the exact binomial distribution
is preferred over other meta-analysis methods
(DerSimonian and Laird, Mantel Haenszel, Peto’s
Odd ratio); as in these data, the event rate is low
with many zero cells (requiring continuity correction
when other methods are used) and comparison arms
(number of patients with/without biomarker of interest)
are highly unequal [21–25]. Univariable meta-analysis
of outcomes will be completed where there are more
than three studies for each outcome, biomarker or
biomarker subgroup. For odds ratios reported as
coefficients and standard errors only, we will use
random effects inverse variance effects (DerSimonian
and Laird) [20].
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 For data that can be extracted as 2 × 2 tables as
sensitivity and specificity, we will use a bivariate
meta-analysis [26] using the “xtmelogit” command
(STATA 14, StataCorp LP, Texas, USA).
 Where 2 × 2 tables can be extracted for biomarkers
at different thresholds, we will present the results
using SROC and where there are sufficient studies
including hierarchical meta-analysis [27]. Results will
be presented for sensitivity values at a fixed specificity
value, based on clinical consensus regarding the relative
potential consequences of over and under diagnosis, i.e.
misclassification costs [28].
 Where IPD data are available, multivariable models
will be fitted to data where more than one
biomarker is included per patient, enabling analysis
of potential confounding between the biomarker and
other predictors.
 Where appropriate, we will use a mixed multilevel
subject-specific (conditional) analysis, fitted by
adaptive Gaussian quadrature using ten integration
points or two if required for model convergence
(using the “xtmelogit” command (STATA 14,
StataCorp LP, Texas, USA).
 Where models do not converge because of inability
to estimate all parameters, we will (i) conduct
separate univariable meta-analysis instead of bivariate
meta-analysis for sensitivity and specificity and (ii) for
data on rare events, results will be pooled as if from a
single study for odds ratios. For meta-analysis of
bivariate outcomes (sensitivity and specificity), where
specificity values are 100%, we will undertake a
univariable meta-analysis of sensitivity and calculate
the exact 95% confidence interval for the 100%
specificity estimate using the total number without
disease across all studies as the denominator [19].
We expect heterogeneity in study estimates due to
variability in outcome definitions, in patient populations,
biomarker test methods, methods for developing models,
and confounding factors. Heterogeneity is often inform-
ative and will be presented via forest plots, ROC plots,
and where there are sufficient studies the presence of
heterogeneity will be tested within meta-analysis. Our
model output will be subject to uncertainty related to
the input variables and we will attempt to quantify this
via sensitivity analysis. Planned sensitivity analyses at
this stage are as follows: for definitions of outcomes
(since exact definitions and/or scales of severe disease
and disease remission are likely to vary between studies),
for different time intervals since diagnosis (since studies
may not be divided simply into those with new and/or
established diagnoses, and definitions of the duration of
established disease will vary by study) and restricted to
studies with low or uncertain bias (i.e. excluding those
with a high likelihood of bias). Planned sensitivity ana-
lyses are detailed in Additional file 1.
Systematic review registration
This systematic review is registered with PROSPERO:
CRD42016029363.
Model development and validation
Where existing models or biomarkers are identified that
can be externally validated using our own IPD, we will
examine individual predictors and predictors in combin-
ation, both using predictor weightings from identified
models and using predictor weightings from our own
models developed using predefined predictor combina-
tions. We will express results in terms of calibration, dis-
crimination, sensitivity at a fixed specificity identified by
our panel as clinically relevant [29]. We may update
these models by recalibration where applicable. We will
seek further IPD datasets and information from authors
where additional details are needed to allow validation.
Ultimately, we wish to provide an overall synthesis of
evidence from the systematic review, univariable ana-
lysis, and any models developed and validated via IPD.
We will interpret clinical utility in conjunction with our
expert panels and provide recommendations and guid-
ance. Finally, we will propose a model and trial design to
tune/test this in a subsequent larger prospective external
validation.
Patient and public involvement (PPI)
We have included a patient as a collaborator on this re-
search so as to facilitate patient and public involvement.
He will facilitate access to patients and their representa-
tive groups and will help the investigators maintain a
patient-centric focus to the proposed research.
Discussion
At the time of writing, there are many narrative reviews
that describe a large variety of individual biomarkers po-
tentially applicable to Crohn’s disease, the research data
arising from their investigation, and their potential appli-
cation in clinical practice. However, it is our experience
that none of these reviews assemble the totality of avail-
able information regarding biomarkers (much of which
is contradictory) into a format that clinicians can use to
guide their day-to-day management of individual pa-
tients. For that reason, clinicians need urgently a system-
atic review that summarises the current literature.
Clinicians also seek a model that combines values from
disparate biomarkers to provide a unified and compre-
hensible metric that describes the overall picture of
prognosis and disease trajectory in an individual patient.
This information could then be used to guide the thera-
peutic decision whether or not to administer early
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biological therapy when balanced against the risks and
costs of prescribing. Therefore, this systematic review
will identify potential biomarkers and models that may
have utility to identify those patients destined to develop
severe Crohn’s disease in the future. We will identify the
most promising predictors and, where possible, test
them using IPD in the context of a prognostic model.
While we do not anticipate identifying a substantial
number of models, if any, it is possible that existing pre-
dictive models of biomarkers exist. If so, these will need
validation using IPD and possible incorporation into our
own model if found sufficiently predictive.
The clinical utility of predictive biomarkers is hindered
greatly by the fact that evidence levels for individual bio-
markers varies widely and many have not been studied
with sufficient methodological rigor to recommend clin-
ical application. For example, while increased levels of a
biomarker (e.g. in blood and stool) may occur in patients
with Crohn’s disease, evidence of how this can be used
to predict subsequent patient outcomes is usually weak.
Our preparatory examination of the available literature
suggests the best existing evidence is available for CRP
and calprotectin. An evidence-based review of current
biomarker models, biomarkers suitable for inclusion in
models, prioritisation of model(s) for external validation,
and external validation of models with IPD biomarkers
would have considerable clinical utility.
It is important to understand that response to bio-
logical therapy is not universal, and that not all patients
destined to develop severe disease will necessarily bene-
fit from their early administration. It is our belief that a
systematic review to identify biomarkers associated with
response to biological therapy could be useful in that
these biomarkers could be integrated into an overall
model that considered both predictions of disease sever-
ity and therapeutic response. This may form the basis of
future work should the current model be found suffi-
ciently predictive.
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